Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia

Journal of Clinical Investigation

Volumn 124, Issue 2, 2014, Pages 644-655

  Gutierrez, Alejandro ^a,b   Pan, Li ^c   Groen, Richard W J ^a,d   Baleydier, Frederic ^c,e   Kentsis, Alex ^a,b   Marineau, Jason ^a   Grebliunaite, Ruta ^a   Kozakewich, Elena ^a   Reed, Casie ^a   Pflumio, Francoise ^f,g   Poglio, Sandrine ^f,g   Uzan, Benjamin ^f,g   Clemons, Paul ^h   VerPlank, Lynn ^h   An, Frank ^h   Burbank, Jason ^h   Norton, Stephanie ^h   Tolliday, Nicola ^h   Steen, Hanno ^b   Weng, Andrew P ⁱ   Yuan, Huipin ^j   Bradner, James E ^a   Mitsiades, Constantine ^a   Look, A Thomas ^a,b   Aster, Jon C ^c   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e HOSPICES CIVILS DE LYON   (France)

^f INSTITUT DE RADIOBIOLOGIE CELLULAIRE ET MOLÉCULAIRE   (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h BROAD INSTITUTE OF MIT AND HARVARD   (United States)

ⁱ BRITISH COLUMBIA CANCER AGENCY   (Canada)

^j XPand Biotechnology BV   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; ANIMALS, GENETICALLY MODIFIED; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; CHROMATOGRAPHY, AFFINITY; DISEASE MODELS, ANIMAL; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MASS SPECTROMETRY; MICE; PERPHENAZINE; PHENOTHIAZINES; PHOSPHORYLATION; PIGMENTATION; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN PHOSPHATASE 2; PROTEOMICS; RECEPTORS, NOTCH; TIME FACTORS; ZEBRAFISH;

EID: 84893871283     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI65093     Document Type: Article

References (74)

1. Marks DI, et al. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics and outcome from the large randomised prospective trial (UKALL XII/ECOG 2993). Blood. 2009;114(25):5136-5145.
2. Goldberg JM, et al. Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J Clin Oncol. 2003;21(19):3616-3622.
3. Ko RH, et al. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study. J Clin Oncol. 2010; 28(4):648-654.
4. Koch U, Radtke F. Notch in T-ALL: new players in a complex disease. Trends Immunol. 2011;32(9):434-442.
5. Kopan R, Ilagan MX. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell. 2009;137(2):216-233.
6. Weng AP, et al. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/ lymphoma. Genes Dev. 2006;20(15):2096-2109.
7. Sharma VM, et al. Notch1 contributes to mouse T-cell leukemia by directly inducing the expression of c-myc. Mol Cell Biol. 2006;26(21):8022-8031.
8. Palomero T, et al. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci U S A. 2006;103(48):18261-18266.
9. Chan SM, Weng AP, Tibshirani R, Aster JC, Utz PJ. Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia. Blood. 2007;110(1):278-286.
10. Felsher DW, Bishop JM. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell. 1999; 4(2):199-207.
11. Langenau DM, et al. Myc-induced T cell leukemia in transgenic zebrafish. Science. 2003; 299(5608):887-890.
12. Gutierrez A, et al. Pten mediates Myc oncogene dependence in a conditional zebrafish model of T cell acute lymphoblastic leukemia. J Exp Med. 2011; 208(8):1595-1603.
13. Weng AP, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004;306(5694):269-271.
14. Gutierrez A, et al. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood. 2009;114(3):647-650.
15. Palomero T, Ferrando A. Oncogenic NOTCH1 control of MYC and PI3K: challenges and opportunities for anti-NOTCH1 therapy in T-cell acute lymphoblastic leukemias and lymphomas. Clin Cancer Res. 2008;14(17):5314-5317.
16. Subramaniam PS, et al. Targeting nonclassical oncogenes for therapy in T-ALL. Cancer Cell. 2012; 21(4):459-472.
17. Zhu HG, Tayeh I, Israel L, Castagna M. Different susceptibility of lung cell lines to inhibitors of tumor promotion and inducers of differentiation. J Biol Regul Homeost Agents. 1991;5(2):52-58.
18. Kau TR, et al. A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer Cell. 2003;4(6):463-476.
19. Choi JH, et al. Potential inhibition of PDK1/Akt signaling by phenothiazines suppresses cancer cell proliferation and survival. Ann N Y Acad Sci. 2008; 1138:393-403.
20. Koren J, et al. Facilitating Akt clearance via manipulation of Hsp70 activity and levels. J Biol Chem. 2010; 285(4):2498-2505.
21. Rho SB, Kim BR, Kang S. A gene signature-based approach identifies thioridazine as an inhibitor of phosphatidylinositol-3α-kinase (PI3K)/AKT pathway in ovarian cancer cells. Gynecol Oncol. 2011; 120(1):121-127.
22. Sachlos E, et al. Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell. 2012;149(6):1284- 1297.
23. Langenau DM, Feng H, Berghmans S, Kanki JP, Kutok JL, Look AT. Cre/lox-regulated transgenic zebrafish model with conditional myc-induced T cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2005;102(17):6068-6073.
24. Lister JA, Robertson CP, Lepage T, Johnson SL, Raible DW. nacre encodes a zebrafish microphthalmia-related protein that regulates neuralcrest-derived pigment cell fate. Development. 1999; 126(17):3757-3767.
25. Real PJ, et al. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med. 2009;15(1):50-58.
26. Blackburn JS, et al. Notch signaling expands a premalignant pool of T-cell acute lymphoblastic leukemia clones without affecting leukemia-propagating cell frequency. Leukemia. 2012;26(9):2069-2078.
27. Ashworth TD, et al. Deletion-based mechanisms of Notch1 activation in T-ALL: key roles for RAG recombinase and a conserved internal translational start site in Notch1. Blood. 2010;116(25):5455-5464.
28. Pacheco R, Prado CE, Barrientos MJ, Bernales S. Role of dopamine in the physiology of T-cells and dendritic cells. J Neuroimmunol. 2009;216(1-2):8-19.
29. Horn AS, Post ML, Kennard O. Dopamine receptor blockade and the neuroleptics, a crystallographic study. J Pharm Pharmacol. 1975;27(8):553-563.
30. Jaszczyszyn A, et al. Chemical structure of phenothiazines and their biological activity. Pharmacol Rep. 2012;64(1):16-23.
31. Ong SE, et al. Identifying the proteins to which small-molecule probes and drugs bind in cells. Proc Natl Acad Sci U S A. 2009;106(12):4617-4622.
32. Shi Y. Serine/threonine phosphatases: mechanism through structure. Cell. 2009;139(3):468-484.
33. Virshup DM, Shenolikar S. From promiscuity to precision: protein phosphatases get a makeover. Mol Cell. 2009;33(5):537-545.
34. Mavrakis KJ, et al. Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia. Nat Cell Biol. 2010;12(4):372-379.
35. Sablina AA, Hector M, Colpaert N, Hahn WC. Identification of PP2A complexes and pathways involved in cell transformation. Cancer Res. 2010; 70(24):10474-10484.
36. Hahn K, Miranda M, Francis VA, Vendrell J, Zorzano A, Teleman AA. PP2A regulatory subunit PP2A-B′ counteracts S6K phosphorylation. Cell Metab. 2010; 11(5):438-444.
37. Yeh E, et al. A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol. 2004;6(4):308-318.
38. Arnold HK, Sears RC. Protein phosphatase 2A regulatory subunit B56alpha associates with c-myc and negatively regulates c-myc accumulation. Mol Cell Biol. 2006;26(7):2832-2844.
39. Junttila MR, et al. CIP2A inhibits PP2A in human malignancies. Cell. 2007;130(1):51-62.
40. Chen Z, et al. MAP kinases. Chem Rev. 2001; 101(8):2449-2476.
41. Ugi S, Imamura T, Ricketts W, Olefsky JM. Protein phosphatase 2A forms a molecular complex with Shc and regulates Shc tyrosine phosphorylation and downstream mitogenic signaling. Mol Cell Biol. 2002;22(7):2375-2387.
42. Chiang CW, et al. Protein phosphatase 2A activates the proapoptotic function of BAD in interleukin-3-dependent lymphoid cells by a mechanism requiring 14-3-3 dissociation. Blood. 2001; 97(5):1289-1297.
43. Chiang CW, et al. Protein phosphatase 2A dephosphorylation of phosphoserine 112 plays the gatekeeper role for BAD-mediated apoptosis. Mol Cell Biol. 2003;23(18):6350-6362.
44. Matsuoka Y, Nagahara Y, Ikekita M, Shinomiya T. A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cells. Br J Pharmacol. 2003;138(7):1303-1312.
45. Neviani P, et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest. 2007;117(9):2408-2421.
46. Yost AJ, et al. Defined, serum-free conditions for in vitro culture of primary human T-ALL blasts. Leukemia. 2013;27(6):1437-1440.
47. Cullion K, et al. Targeting the Notch1 and mTOR pathways in a mouse T-ALL model. Blood. 2009; 113(24):6172-6181.
48. DeAngelo DJ, Stone RM, Silverman LB, Aster JC. A phase I clinical trial of the Notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias. J Clin Oncol. 2006;24:6585.
49. Sachlos E, et al. Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell. 2012;149(6):1284- 1297.
50. Zhelev Z, et al. Phenothiazines suppress proliferation and induce apoptosis in cultured leukemic cells without any influence on the viability of normal lymphocytes. Phenothiazines and leukemia. Cancer Chemother Pharmacol. 2004;53(3):267-275.
51. Gil-Ad I, Shtaif B, Levkovitz Y, Dayag M, Zeldich E, Weizman A. Characterization of phenothiazineinduced apoptosis in neuroblastoma and glioma cell lines: clinical relevance and possible application for brain-derived tumors. J Mol Neurosci. 2004; 22(3):189-198.
52. Gil-Ad I, et al. Phenothiazines induce apoptosis in a B16 mouse melanoma cell line and attenuate in vivo melanoma tumor growth. Oncol Rep. 2006; 15(1):107-112.
53. Sangodkar J, et al. Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response. J Clin Invest. 2012;122(7):2637-2651.
54. Chiang MY, et al. Leukemia-associated NOTCH1 alleles are weak tumor initiators but accelerate K-ras-initiated leukemia. J Clin Invest. 2008; 118(9):3181-3194.
55. Gonzalez-Garcia S, et al. CSL-MAML-dependent Notch1 signaling controls T lineage-specific IL-7R{alpha} gene expression in early human thymopoiesis and leukemia. J Exp Med. 2009; 206(4):779-791.
56. Zenatti PP, et al. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nat Genet. 2011;43(10):932-939.
57. Medyouf H, et al. High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling. J Exp Med. 2011;208(9):1809-1822.
58. Dail M, et al. Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents. Proc Natl Acad Sci U S A. 2010;107(11):5106-5111.
59. Subramanyam D, Krishna S. c-Myc substitutes for Notch1-CBF1 functions in cooperative transformation with papillomavirus oncogenes. Virology. 2006;347(1):191-198.
60. Wang H, et al. Genome-wide analysis reveals conserved and divergent features of Notch1/RBPJ binding in human and murine T lymphoblastic leukemia cells. Proc Natl Acad Sci U S A. 2011; 108(36):14908-14913.
61. Palomero T, et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med. 2007;13(10):1203-1210.
62. Kridel R, et al. Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. Blood. 2012;119(9):1963-1971.
63. Di Ianni M, et al. A new genetic lesion in B-CLL: a NOTCH1 PEST domain mutation. Br J Haematol. 2009;146(6):689-691.
64. Fabbri G, et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med. 2011;208(7):1389-1401.
65. Puente XS, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011;475(7354):101-105.
66. Robinson DR, et al. Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nat Med. 2011; 17(12):1646-1651.
67. Liu Q, et al. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood. 2008;111(1):275-284.
68. Liu Q, et al. FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma. Clin Cancer Res. 2010;16(12):3182-3192.
69. Langenau DM, et al. Suppression of apoptosis by bcl-2 overexpression in lymphoid cells of transgenic zebrafish. Blood. 2005;105(8):3278-3285.
70. Seiler KP, et al. ChemBank: a small-molecule screening and cheminformatics resource database. Nucleic Acids Res. 2008;36 (Database issue):D351-359.
71. Armstrong F, et al. NOTCH is a key regulator of human T-cell acute leukemia initiating cell activity. Blood. 2009;113(8):1730-1740.
72. Tallarida RJ. Drug synergism: its detection and applications. J Pharmacol Exp Ther. 2001; 298(3):865-872.
73. Groen RW, et al. Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma. Blood. 2012;120(3):e9-e16.
74. Sablina AA, et al. The tumor suppressor PP2A Abeta regulates the RalA GTPase. Cell. 2007; 129(5):969-982.